Back to state act
Description
On 23 April 2026, the United States announced an agreement with Regeneron under which the company agreed to implement most-favoured-nation pricing for its drugs and to make investments in U.S. manufac...
Sign in or create a free account to see full description
Intervention Details
Intervention Type
Import tariff
MAST Chapter
Tariff measures
Implementation date
No implementation date
Revocation date
No revocation date
Implementation level
National
Affected flow
Inward
Announced as temporary
No
Eligible firms
firm-specific
Affected Trading Partners
Table
Affected Sectors
Sign in to access 2 sectors
Affected Products
Sign in to access 120 products
Threads
See all
Harmful Trade Policy Measures
This Thread tracks harmful trade policy interventions affecting all products. Covering all types of interventions monitored by Global Trade Alert, it highlights how the yearly number of these measures has evolved over time.
Published: 04 Sep 2024
70619
interventions
194
jurisdictions
United States: Drug Pricing Agreements
This Thread tracks the U.S. Administration’s agreements with pharmaceutical companies. It is based on the Executive Order titled “Delivering Most-Favored-Nation (MFN) Prescription Drug Pricing to American Patients.” These agreements include tariff relief measures for pharmaceutical companies in return for their commitments to implement most-favored-nation pricing for their drugs and to invest i...
Published: 11 Nov 2025
68
interventions
2
jurisdictions